Liquidia (NASDAQ:LQDA) PT Raised to $32.00

Liquidia (NASDAQ:LQDA) had its price target lifted by investment analysts at HC Wainwright from $16.00 to $32.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 105.66% from the company’s current price.

Other analysts also recently issued research reports about the stock. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Liquidia in a research report on Wednesday, February 21st. Wedbush reissued an “underperform” rating and set a $3.00 price target on shares of Liquidia in a report on Thursday, December 21st. LADENBURG THALM/SH SH boosted their price target on shares of Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, December 21st. Finally, Bank of America boosted their price target on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.00.

Liquidia Stock Performance

Shares of LQDA stock traded down $0.34 during mid-day trading on Thursday, reaching $15.56. 921,783 shares of the company were exchanged, compared to its average volume of 984,532. Liquidia has a fifty-two week low of $5.71 and a fifty-two week high of $16.51. The company has a market capitalization of $1.18 billion, a P/E ratio of -13.05 and a beta of 0.14. The business’s 50 day simple moving average is $13.71 and its 200 day simple moving average is $9.61.

Hedge Funds Weigh In On Liquidia

Several institutional investors and hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD grew its stake in shares of Liquidia by 9.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company’s stock valued at $137,000 after buying an additional 989 shares in the last quarter. SkyView Investment Advisors LLC grew its stake in shares of Liquidia by 1.4% in the 4th quarter. SkyView Investment Advisors LLC now owns 111,571 shares of the company’s stock valued at $1,342,000 after buying an additional 1,571 shares in the last quarter. BNP Paribas Arbitrage SNC grew its holdings in Liquidia by 20.5% during the first quarter. BNP Paribas Arbitrage SNC now owns 9,993 shares of the company’s stock valued at $69,000 after purchasing an additional 1,702 shares during the last quarter. Chartwell Investment Partners LLC grew its holdings in Liquidia by 6.0% during the fourth quarter. Chartwell Investment Partners LLC now owns 31,024 shares of the company’s stock valued at $197,000 after purchasing an additional 1,769 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Liquidia by 7.1% during the fourth quarter. JPMorgan Chase & Co. now owns 27,923 shares of the company’s stock valued at $178,000 after purchasing an additional 1,845 shares during the last quarter. Hedge funds and other institutional investors own 45.03% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.